1. Mutational spectrum of WTX, WT1, CTNNB1, APC and PLCG2 genes in Wilms tumor defined by massive parallel resequencing
- Author
-
Bruna D. F. Barros, Mariana Maschietto, Dirce Maria Carraro, Elisa Napolitano Ferreira, Ana Cv Krepíschi, and Giovana Tardin Torrezan
- Subjects
Genetics ,Candidate gene ,Mutation ,Point mutation ,lcsh:R ,lcsh:Medicine ,Wilms' tumor ,General Medicine ,Amplicon ,Biology ,medicine.disease_cause ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,DNA sequencing ,Exon ,Poster Presentation ,medicine ,lcsh:Q ,Indel ,lcsh:Science - Abstract
Background The identification of molecular alterations that trigger Wilms tumor (WT) development is crucial to understanding the tumorigenesis of this malignancy. Currently, it is estimated that WTX and WT1 genomic losses together with CTNNB1 point mutations occur in about 30% of WTs. However, the majority of cases remain without any identified driver mutation. Results from a previous study by our group pointed to APC and PLCG2 as candidate genes altered in WT [1]. Given the advent of modern DNA sequencing technologies, it is now feasible to evaluate large genomic regions spanning complete genes (exons and introns), allowing the description of the mutation patterns occurring in tumor cells. Thus, the aim of this study was to identify point mutations and indels in the complete sequence of APC, CTNNB1, WT1, WTX and PLCG2 genes in order to characterize both the exonic mutational spectrum and the intronic nucleotide substitution pattern. Material and methods The complete genomic regions of the selected genes, spanning a total of 430 kb, were amplified by long-range PCR in 15 WTs and 3 non-neoplasic control samples, giving a total of 60 amplicons per sample (10 kb on average). The resulting amplicons were mixed at equimolar concentrations and, for each sample, the Ion PGM library preparation protocol was performed. The libraries of the 18 barcoded samples were combined in four sequencing pools that were individually submitted to an Ion PGM™ Sequencer run on an Ion 316™ Chip. Point mutation and indels not present in the non-neoplasic controls were selected for capillary sequencing validation. The validated
- Published
- 2012